Involvement of PI3K-Akt-Bad pathway in apoptosis induced by 2,6-di-O-methyl-β-cyclodextrin, not 2,6-di-O-methyl-α-cyclodextrin, through cholesterol depletion from lipid rafts on plasma membranes in cells

European Journal of Pharmaceutical Sciences

Volumn 38, Issue 3, 2009, Pages 249-261

  Motoyama, Keiichi ^a   Kameyama, Kazuhisa ^a   Onodera, Risako ^a   Araki, Norie ^b   Hirayama, Fumitoshi ^c   Uekama, Kaneto ^c   Arima, Hidetoshi ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

^c SOJO UNIVERSITY   (Japan)

Author keywords

2,6 Di O methyl cyclodextrin; 2,6 Di O methyl cyclodextrin; Apoptosis; Cholesterol; Lipid rafts; PI3K Akt Bad

Indexed keywords

2 HYDROXYPROPYL ALPHA CYCLODEXTRIN; 2 HYDROXYPROPYL BETA CYCLODEXTRIN; 2,3,6 O TRIMETHYL BETA CYCLODEXTRIN; 2,6 O DIMETHYL ALPHA CYCLODEXTRIN; 2,6 O DIMETHYL BETA CYCLODEXTRIN; BETA CYCLODEXTRIN SULFOBUTYL ETHER; CYCLODEXTRIN DERIVATIVE; CYTOCHROME C; METHYL BETA CYCLODEXTRIN; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; PROCASPASE 3; PROTEIN BAD; PROTEIN KINASE B; PROTEIN P53; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL MEMBRANE; CELL VIABILITY; CHROMATIN CONDENSATION; CONTROLLED STUDY; DNA FRAGMENTATION; DOWN REGULATION; HUMAN; HUMAN CELL; LIPID RAFT; METHYLATION; MITOCHONDRIAL MEMBRANE POTENTIAL; NONHUMAN; PRIORITY JOURNAL;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ALPHA-CYCLODEXTRINS; ANIMALS; APOPTOSIS; BCL-ASSOCIATED DEATH PROTEIN; BETA-CYCLODEXTRINS; CELLS, CULTURED; CHOLESTEROL; HUMANS; JURKAT CELLS; MEMBRANE MICRODOMAINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 70349124557     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2009.07.010     Document Type: Article

References (57)

1. Allen D.L., Linderman J.K., Roy R.R., Bigbee A.J., Grindeland R.E., Mukku V., and Edgerton V.R. Apoptosis: a mechanism contributing to remodeling of skeletal muscle in response to hindlimb unweighting. Am. J. Physiol. 273 (1997) C579-587
2. Ashkenazi A. Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat. Rev. Drug Discov. 7 (2008) 1001-1012
3. Ayllon V., Fleischer A., Cayla X., Garcia A., and Rebollo A. Segregation of Bad from lipid rafts is implicated in the induction of apoptosis. J. Immunol. 168 (2002) 3387-3393
4. Bollinger C.R., Teichgraber V., and Gulbins E. Ceramide-enriched membrane domains. Biochim. Biophys. Acta 1746 (2005) 284-294
5. Brown D.A., and London E. Functions of lipid rafts in biological membranes. Annu. Rev. Cell Dev. Biol. 14 (1998) 111-136
6. Burger K., Gimpl G., and Fahrenholz F. Regulation of receptor function by cholesterol. Cell Mol. Life Sci. 57 (2000) 1577-1592
7. Cardone M.H., Roy N., Stennicke H.R., Salvesen G.S., Franke T.F., Stanbridge E., Frisch S., and Reed J.C. Regulation of cell death protease caspase-9 by phosphorylation. Science 282 (1998) 1318-1321
8. Chen D., Zhang J., Li M., Rayburn E.R., Wang H., and Zhang R. RYBP stabilizes p53 by modulating MDM2. EMBO Rep. 10 (2009) 166-172
9. Crowder C.M. Cell biology. Ceramides-friend or foe in hypoxia?. Science 324 (2009) 343-344
10. Davis R.J. Signal transduction by the JNK group of MAP kinases. Cell 103 (2000) 239-252
11. Dobrowsky R.T. Sphingolipid signalling domains floating on rafts or buried in caves?. Cell Signal. 12 (2000) 81-90
12. Dykstra M., Cherukuri A., Sohn H.W., Tzeng S.J., and Pierce S.K. Location is everything: lipid rafts and immune cell signaling. Annu. Rev. Immunol. 21 (2003) 457-481
13. Edidin M. The state of lipid rafts: from model membranes to cells. Annu. Rev. Biophys. Biomol. Struct. 32 (2003) 257-283
14. Edinger A.L., and Thompson C.B. Death by design: apoptosis, necrosis and autophagy. Curr. Opin. Cell Biol. 16 (2004) 663-669
15. Emaus R.K., Grunwald R., and Lemasters J.J. Rhodamine 123 as a probe of transmembrane potential in isolated rat-liver mitochondria: spectral and metabolic properties. Biochim. Biophys. Acta 850 (1986) 436-448
16. Fauvelle F., Debouzy J.C., Crouzy S., Goschl M., and Chapron Y. Mechanism of α-cyclodextrin-induced hemolysis. 1. The two-step extraction of phosphatidylinositol from the membrane. J. Pharm. Sci. 86 (1997) 935-943
17. Franke T.F., Hornik C.P., Segev L., Shostak G.A., and Sugimoto C. PI3K/Akt and apoptosis: size matters. Oncogene 22 (2003) 8983-8998
18. Fridman J.S., and Lowe S.W. Control of apoptosis by p53. Oncogene 22 (2003) 9030-9040
19. Gniadecki R. Depletion of membrane cholesterol causes ligand-independent activation of Fas and apoptosis. Biochem. Biophys. Res. Commun. 320 (2004) 165-169
20. Goule S., and Scott R.C. 2-Hydroxypropyl-β-cyclodextrin (HP-β-CD): A toxicology review. Food Chem. Toxicol. 43 (2005) 1451-1459
21. Grassme H., Schwarz H., and Gulbins E. Molecular mechanisms of ceramide-mediated CD95 clustering. Biochem. Biophys. Res. Commun. 284 (2001) 1016-1030
22. Grosse P.Y., Bressolle F., and Pinguet F. Antiproliferative effect of methyl-β-cyclodextrin in vitro and in human tumour xenografted athymic nude mice. Br. J. Cancer 78 (1998) 1165-1169
23. Hamasaki K., Kogure K., and Ohwada K. A biological method for the quantitative measurement of tetrodotoxin (TTX): tissue culture bioassay in combination with a water-soluble tetrazolium salt. Toxicon 34 (1996) 490-495
24. Hueber A.O., Bernard A.M., Herincs Z., Couzinet A., and He H.T. An essential role for membrane rafts in the initiation of Fas/CD95-triggered cell death in mouse thymocytes. EMBO Rep. 3 (2002) 190-196
25. Irie T., and Uekama K. Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. J. Pharm. Sci. 86 (1997) 147-162
26. Irie T., and Uekama K. Cyclodextrins in peptide and protein delivery. Adv. Drug Deliv. Rev. 36 (1999) 101-123
27. Irie T., Otagiri M., Sunada M., Uekama K., Ohtani Y., Yamada Y., and Sugiyama Y. Cyclodextrin-induced hemolysis and shape changes of human erythrocytes in vitro. J. Pharmacobiodyn. 5 (1982) 741-744
28. Kabouridis P.S., Janzen J., Magee A.L., and Ley S.C. Cholesterol depletion disrupts lipid rafts and modulates the activity of multiple signaling pathways in T lymphocytes. Eur. J. Immunol. 30 (2000) 954-963
29. Kim R., Emi M., and Tanabe K. Caspase-dependent and -independent cell death pathways after DNA damage (review). Oncol. Rep. 14 (2005) 595-599
30. Kroemer G., and Reed J.C. Mitochondrial control of cell death. Nat. Med. 6 (2000) 513-519
31. Lacour S., Hammann A., Grazide S., Lagadic-Gossmann D., Athias A., Sergent O., Laurent G., Gambert P., Solary E., and Dimanche-Boitrel M.T. Cisplatin-induced CD95 redistribution into membrane lipid rafts of HT29 human colon cancer cells. Cancer Res. 64 (2004) 3593-3598
32. Lavrik I.N., Golks A., and Krammer P.H. Caspases: pharmacological manipulation of cell death. J. Clin. Invest. 115 (2005) 2665-2672
33. Le Roy C., and Wrana J.L. Clathrin- and non-clathrin-mediated endocytic regulation of cell signalling. Nat. Rev. Mol. Cell Biol. 6 (2005) 112-126
34. Legler D.F., Micheau O., Doucey M.A., Tschopp J., and Bron C. Recruitment of TNF receptor 1 to lipid rafts is essential for TNFα-mediated NF-κB activation. Immunity 18 (2003) 655-664
35. Leu J.I., Dumont P., Hafey M., Murphy M.E., and George D.L. Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat. Cell Biol. 6 (2004) 443-450
36. Li Y.C., Park M.J., Ye S.K., Kim C.W., and Kim Y.N. Elevated levels of cholesterol-rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-depleting agents. Am. J. Pathol. (2006) 168, 1107-1118; quiz 1404-1105
37. Loos B., and Engelbrecht A.M. Cell death: a dynamic response concept. Autophagy (2009) 5
38. Mejillano M., Yamamoto M., Rozelle A.L., Sun H.Q., Wang X., and Yin H.L. Regulation of apoptosis by phosphatidylinositol 4,5-bisphosphate inhibition of caspases, and caspase inactivation of phosphatidylinositol phosphate 5-kinases. J. Biol. Chem. 276 (2001) 1865-1872
39. Motoyama K., Toyodome H., Onodera R., Irie T., Hirayama F., Uekama K., and Arima H. Involvement of lipid rafts of rabbit red blood cells in morphological changes induced by methylated β-cyclodextrins. Biol. Pharm. Bull. 32 (2009) 700-705
40. Ohtani Y., Irie T., Uekama K., Fukunaga K., and Pitha J. Differential effects of α-, β- and γ-cyclodextrins on human erythrocytes. Eur. J. Biochem. 186 (1989) 17-22
41. Ono N., Arima H., Hirayama F., and Uekama K. A moderate interaction of maltosyl-α-cyclodextrin with Caco-2 cells in comparison with the parent cyclodextrin. Biol. Pharm. Bull. 24 (2001) 395-402
42. Parpal S., Karlsson M., Thorn H., and Stralfors P. Cholesterol depletion disrupts caveolae and insulin receptor signaling for metabolic control via insulin receptor substrate-1, but not for mitogen-activated protein kinase control. J. Biol. Chem. 276 (2001) 9670-9678
43. Pettus B.J., Chalfant C.E., and Hannun Y.A. Ceramide in apoptosis: an overview and current perspectives. Biochim. Biophys. Acta 1585 (2002) 114-125
44. Rajewski R.A., Traiger G., Bresnahan J., Jaberaboansari P., Stella V.J., and Thompson D.O. Preliminary safety evaluation of parenterally administered sulfoalkyl ether b-cyclodextrin derivatives. J. Pharm. Sci. 84 (1995) 927-932
45. Shimizu S., Narita M., and Tsujimoto Y. Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC. Nature 399 (1999) 483-487
46. Shimizu S., Matsuoka Y., Shinohara Y., Yoneda Y., and Tsujimoto Y. Essential role of voltage-dependent anion channel in various forms of apoptosis in mammalian cells. J. Cell Biol. 152 (2001) 237-250
47. Simons K., and Toomre D. Lipid rafts and signal transduction. Nat. Rev. Mol. Cell Biol. 1 (2000) 31-39
48. Szente L., and Szejtli J. Highly soluble cyclodextrin derivatives: chemistry, properties, and trends in development. Adv. Drug Deliv. Rev. 36 (1999) 17-28
49. Taatjes D.J., Sobel B.E., and Budd R.C. Morphological and cytochemical determination of cell death by apoptosis. Histochem. Cell Biol. 129 (2008) 33-43
50. Tu H.C., Ren D., Wang G.X., Chen D.Y., Westergard T.D., Kim H., Sasagawa S., Hsieh J.J., and Cheng E.H. The p53-cathepsin axis cooperates with ROS to activate programmed necrotic death upon DNA damage. Proc. Natl. Acad. Sci. U.S.A. 106 (2009) 1093-1098
51. Uekama K., Hirayama F., and Irie T. Cyclodextrin drug carrier systems. Chem. Rev. 98 (1998) 2045-2076
52. Wang X. The expanding role of mitochondria in apoptosis. Genes Dev. 15 (2001) 2922-2933
53. L and Bcl-2, displaces Bax and promotes cell death. Cell 80 (1995) 285-291
54. Yang J., Liu X., Bhalla K., Kim C.N., Ibrado A.M., Cai J., Peng T.I., Jones D.P., and Wang X. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 275 (1997) 1129-1132
55. Yunomae K., Arima H., Hirayama F., and Uekama K. Involvement of cholesterol in the inhibitory effect of dimethyl-β-cyclodextrin on P-glycoprotein and MRP2 function in Caco-2 cells. FEBS Lett. 536 (2003) 225-231
56. Zha J., Harada H., Yang E., Jockel J., and Korsmeyer S.J. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 87 (1996) 619-628
57. Zong W.X., Ditsworth D., Bauer D.E., Wang Z.Q., and Thompson C.B. Alkylating DNA damage stimulates a regulated form of necrotic cell death. Genes Dev. 18 (2004) 1272-1282